Avacta Group PLC Notice of Results (5988B)
08 October 2015 - 5:00PM
UK Regulatory
TIDMAVCT
RNS Number : 5988B
Avacta Group PLC
08 October 2015
08 October 2015
Avacta Group plc
("Avacta" or "the Group")
Notice of Results
Avacta Group plc (AIM: AVCT), the developer of Affimer(R)
biotherapeutics and research reagents, expects to announce its
preliminary results for the year ended 31 July 2015 on Monday 26
October 2015.
Enquiries:
Avacta Group plc Tel: +44 (0) 844 414
Alastair Smith, Chief Executive Officer 0452
Tim Sykes, Chief Financial Officer www.avacta.com
Numis Securities Limited Tel: +44 (0) 207 260
Michael Meade / Freddie Barnfield - Nominated 1000
Adviser www.numiscorp.com
James Black - Corporate Broking
WG Partners Tel: +44 (0) 203 705
David Wilson 9318
Nigel Barnes Tel: +44 (0) 203 705
Claes Spang 9217
www.wgpartners.co.uk
Media Enquiries Tel: +44 (0) 20 3727
FTI Consulting 1000
Simon Conway/Natalie Garland-Collins avacta@fticonsulting.com
Notes to Editors
Avacta Group plc (www.avacta.com)
Avacta Group plc is a global provider of innovative
technologies, consumables and reagents for the life science
markets, from drug discovery to diagnostics. Avacta's principal
focus is on its proprietary Affimer(R) technology which is a novel
engineered alternative to antibodies that has wide application in
Life Sciences for diagnostics, therapeutics and general research
and development.
Antibodies dominate markets worth in excess of $50bn despite
their shortcomings. Affimers have been designed to address many of
these negative performance issues, principally: the time taken to
generate new antibodies, the reliance on an animal's immune
response, poor specificity in many cases, and batch to batch
variability. Affimers are based on a small protein that can be
quickly generated to bind with high specificity and affinity to a
wide range of protein targets.
Avacta is commercialising Affimer reagents through custom
Affimer services to provide bespoke solutions to customers, via a
growing on-line catalogue of Affimer reagents and, in the longer
term, by developing Affimers with therapeutic properties for
out-licensing.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORFSAFWWFISEES
(END) Dow Jones Newswires
October 08, 2015 02:00 ET (06:00 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024